A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
Key facts
- Who runs it
- Pfizer
- Where
- Brownsville, Columbus, Dublin, Gurnee, Hartsdale, Hialeah, Houston, Huntington Beach, Lake City, Lake Forest, Las Vegas, Melbourne, Mesquite, Miami, Midlothian, Milford, Nashville, North Charleston, North Las Vegas, Peoria, Salt Lake City, San Antonio, San Diego, Springfield, Tomball, Tustin, Walnut Creek, Wilmington, and Winter Park, United StatesSee the 37 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 1,142 people enrolled
- Started
- 5 Jun 2023
- Ended
- 1 Jan 2024
- Type of study
- Interventional, 7 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Combination [RSVpreF+BNTb162b2]
- Bivalent BNT162b2 (original/Omi BA.4/BA.5)
- RSVpreF
- QIV
- Normal Saline Placebo
- Record updated
- 18 December 2024
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Other criteria
- Substudy A Inclusion Criteria:
- Male or female participants ≥65 years of age at Visit 1 (Day 1)
- Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
- Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol
- Participants who have received at least 3 prior US authorized mRNA COVID 19 vaccines, with the last dose being an updated (bivalent) vaccine given at least ≥150 days before Visit A101 (Day 1); Substudy A Exclusion Criteria:
- A confirmed diagnosis of COVID 19, RSV infection, or influenza ≤120 days before study intervention administration
- History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
- Allergy to egg proteins (egg or egg products) or chicken proteins
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
- Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
- Receipt of any RSV vaccine at any time prior to enrollment, or planned receipt throughout the study
- Receipt of any influenza vaccine ≤120 days before study enrollment
- Participation in other studies involving a study intervention within 28 days before randomization. Anticipated participation in other studies within 28 days after receipt of study intervention in this study
- Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
Where in United States
- Headlands Horizons LLCBrownsville, United States
- Centricity Research Columbus Ohio MultispecialtyColumbus, United States
- West Coast ResearchDublin, United States
- Great Lakes Clinical Trials - GurneeGurnee, United States
- Drug Trials AmericaHartsdale, United States
- Indago Research & Health Center, IncHialeah, United States
- DM Clinical Research - BellaireHouston, United States
- DM Clinical Research - Cy FairHouston, United States
- DM Clinical Research- CyfairHouston, United States
- Marvel Clinical ResearchHuntington Beach, United States
- Wr-Msra,LlcLake City, United States
- Orange County Research CenterLake Forest, United States
- Las Vegas Clinical TrialsLas Vegas, United States
- Optimal ResearchMelbourne, United States
- SMS Clinical ResearchMesquite, United States
- Suncoast Research GroupMiami, United States
- Virginia Research CenterMidlothian, United States
- Clinical Research ConsultingMilford, United States
- Clinical Research Associates, Inc.Nashville, United States
- Coastal Carolina Research CenterNorth Charleston, United States
- Las Vegas Clinical TrialsNorth Las Vegas, United States
- Optimal ResearchPeoria, United States
- J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United States
- J. Lewis Research, Inc. / Foothill Family Clinic SouthSalt Lake City, United States
- Clinical Trials of Texas LLCSan Antonio, United States
- Artemis Institute for Clinical ResearchSan Diego, United States
- California Research FoundationSan Diego, United States
- Bio-Kinetic Clinical Applications LLC DBA QPS_MO (Patient Screening Only)Springfield, United States
- Bio-Kinetic Clinical Applications, LLC dba QPS-MOSpringfield, United States
- Bio-Kinetic Clinical Applications, LLD dba QPS-MOSpringfield, United States
- DM Clinical Research - Martin Diagnostic ClinicTomball, United States
- Orange County Research CenterTustin, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
- Accellacare - WilmingtonWilmington, United States
- Accellacare - Wilmington - 1917 Tradd CourtWilmington, United States
- Clinical Site Partners, LLC DBA CSP OrlandoWinter Park, United States
- Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United States
About the trial
What the trial wants to find out
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections.
Read full original descriptionShow less
This study is seeking participants who:
* are 65 years of age or older. * are healthy or have well-controlled chronic conditions. * in the past have received at least 3 US-authorized mRNA COVID 19 vaccines, with the most recent vaccine being an updated booster vaccine given at least more than or equal to 150 days before Visit A101 (Day 1). * have not had a flu shot in the last 120 days. * agree to be present for all study visits, procedures, and blood draws.
Participants will be involved in this study for 6 months. During this time, participants will have 2 study visits at the study clinic and a 6-month telephone contact.
The 7 groups in the trial
- Group 1Treatment being tested
Combination \[RSVpreF+BNT162b2\] + Quadrivalent influenza vaccine (QIV)
Treatment: Combination [RSVpreF+BNTb162b2] and QIV
- Group 2Treatment being tested
Combination \[RSVpreF+BNT162b2\] + placebo
Treatment: Combination [RSVpreF+BNTb162b2] and Normal Saline Placebo
- Group 3Existing treatment, for comparison
BNT162b2 + placebo
Treatment: Bivalent BNT162b2 (original/Omi BA.4/BA.5) and Normal Saline Placebo
- Group 4Existing treatment, for comparison
RSVpreF + placebo
Treatment: RSVpreF and Normal Saline Placebo
- Group 5Existing treatment, for comparison
QIV + placebo
Treatment: QIV and Normal Saline Placebo
- Group 6Treatment being tested
Coadministration RSVpreF + bivalent BNT162b2 + placebo
Treatment: Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, and Normal Saline Placebo
- Group 7Treatment being tested
Coadministration RSVpreF + bivalent BNT162b2 + QIV
Treatment: Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, and QIV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS
- Publications
- Record updated
- 18 December 2024